Diligence memo · auto-generated · as of July 2, 2026

Inceptor Bio, LLC

Inceptor Bio, LLC looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Inceptor Bio, LLC operates in Biotechnology, based in MORRISVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Inceptor Bio, LLC has raised $60M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $38M on 2022-02-17.

Most recent recorded round closed around 2025-01-17.

Valuation (modeled)modeled

Provath models Inceptor Bio, LLC at approximately $18M (range $6.5M–$30M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.24× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 11 months.

Last raise 17 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round stepped up 1.2× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 84% of Biotechnology peers (4293 compared).

Modeled value ranks above 27% of those peers.

Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..

Peoplefiled

18 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.